Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 30, 2010

Critical Biologics to Use Scarab’s Clean Genome E. coli for Production of Phase II Gelsolin Replacement Therapy

  • Critical Biologics negotiated a license to Scarab Genomics’ Clean Genome® E. coli platform for the production of its Phase II-stage recombinant human plasma gelsolin (rhu-pGSN), Solinex. The deal also allows Scarab to use rhu-pGSN as a test protein for demonstrating its bacterial production technology to prospective clients.

    Critical Genomics says the Clean Genome E. coli technology appears to significantly maximize production efficiency and optimize cloning performance. “We have been deeply impressed by Scarab’s fivefold increase in production yield to over 13 g/L at 5 L batch scale,” remarked Ashleigh Palmer, Critical Genomics’ CEO.

    Scarab Genomics’ Clean Genome E. coli is an engineered K12 strain in which over 15% of the genome has been deleted, including transposable insertion sequences and prophage. The firm claims this genome reduction optimizes E. coli as a biological factory, with elimination of nonessential genes as well as recombinogenic or mobile DNA, toxins, and virulence genes provides increased genome and plasmid stability and improved metabolic efficiency.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »